Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells pulsed with hepatitis c virus core and nonstructural protein 3 antigens
- Development stage
- Phase 2
- Lead developer
- Gamaleya Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intracutaneous
01
Overview
Autologous dendritic cells pulsed with hepatitis C virus (HCV) core and nonstructural protein 3 (NS3) antigens is a therapeutic vaccine designed to treat chronic HCV infection. This cell-based immunotherapy involves isolating a patient's own dendritic cells (autologous), which are then loaded (pulsed) ex vivo with recombinant HCV core and NS3 proteins. These antigen-presenting cells are subsequently re-administered to the patient, where they are intended to stimulate a robust and specific adaptive immune response, including both CD4+ and CD8+ T-cell responses, against the Hepatitis C virus. The goal is to enhance the body's ability to clear the virus or significantly reduce its viral load, addressing the immune evasion mechanisms often seen in chronic HCV infection.
- Other names
- Autologous DC-vaccinesAutologous dendritic cells pulsed with recombinant HCV-antigens (Core and NS3)
02
Targets
NS3 (Dengue virus NS3 protein)Core (Hepatitis C virus core protein)
Beyond the preview
Go deeper on autologous dendritic cells pulsed with hepatitis c virus core and nonstructural protein 3 antigens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells pulsed with hepatitis c virus core and nonstructural protein 3 antigens.